Purpose: to evaluate the safety and tolerability of a potential new drug for the purpose of treating ER+/HER2 breast cancer.
Participate in a clinical study of a potential treatment for metastatic breast cancer.
This study has 1 screening appointment and 3 stays each 8 nights/ 9 days.
Reimbursement for study participation will be provided for time and travel of up to $12,529.
Participants will dose 3 times in this study to evaluate different tablet formulations in fed conditions.
This study has been reviewed by an Institutional Review Board.
Call 612-315-6490 to discuss your eligibility today!